What is GenePeeks?
GenePeeks operates at the forefront of the computational genomics sector, providing a sophisticated platform that digitally simulates the genetic interactions of two potential parents. By creating and analyzing thousands of Virtual Progeny, the company offers a unique, physician-ordered testing service that uncovers disease risks often missed by conventional screening methodologies. Founded by Anne Morriss and Dr. Lee Silver, the organization bridges the gap between academic molecular biology and clinical application, aiming to provide families with actionable insights into hereditary health. Its market position is reinforced by a leadership team with deep expertise in medical diagnostics and biotechnology, ensuring that its clinical laboratory services meet the rigorous standards required for high-stakes genetic analysis.
How much funding has GenePeeks raised?
GenePeeks has raised a total of $38.8M across 5 funding rounds:
Series A
$5.3M
Debt
$3M
Private Equity
$10M
Series B
$16M
Other Financing Round
$4.5M
Series A (2012): $5.3M with participation from Columbus Nova Technology Partners
Debt (2014): $3M led by Horizon Technology
Private Equity (2016): $10M, investors not publicly disclosed
Series B (2017): $16M featuring Columbus Nova Technology Partners, 5AM Ventures, Alexandria Real Estate Equities, and Alta Partners
Other Financing Round (2017): $4.5M backed by Bridge Bank
Key Investors in GenePeeks
Columbus Nova Technology Partners
Columbus Nova is an investment company founded in 2000 by Andrew Intrater, who serves as the company's chief executive officer and is cousin to Russian oligarch Viktor Vekselberg.
5AM Ventures
Five AM Ventures is a life science focused venture capital firm that backs early stage biotech and health care innovators, partnering closely with founders to shape companies, fund rigorous science and help bring new therapies and technologies to patients.
Alexandria Real Estate Equities
Alexandria Real Estate Equities, Inc., a real estate investment trust (REIT), engages in the ownership, operation, management, development, acquisition, and redevelopment of properties for the life sciences industry.
What's next for GenePeeks?
With the recent influx of capital, GenePeeks is well-positioned to accelerate its commercial expansion and enhance its clinical laboratory infrastructure. The strategic focus will likely shift toward broadening the adoption of its proprietary platform among healthcare providers and integrating its analytics into standard reproductive health workflows. As the company moves beyond its initial development phase, the emphasis will remain on scaling its computational engine to handle larger datasets, thereby increasing the precision and accessibility of its inherited disease risk assessments. Future growth will be driven by the continued validation of its technology and the expansion of its footprint within the global life sciences market.
See full GenePeeks company page
